The long-term impact of 2 – 3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women

References

• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, et al. for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Speroff L. WHI trial: it's time to be critical!. Am J Obstet Gynecol 2003; 189: 620
   PubMed Web of Science ®Google Scholar
• Herrington D M, Howard T D. From presumed benefit to potential harm – hormone therapy and heart disease. N Engl J Med 2003; 349: 519–521
   PubMed Web of Science ®Google Scholar
• Notelovitz M. The clinical practice impact of the Women's Health Initiative: political vs. biologic correctness. Maturitas 2003; 44: 3–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Clarkson T B, Manson J E. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645–650
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Colditz G A, Willett W C, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756–762
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Manson J E, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Colditz G A, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–1775
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Koh K K, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. Arterioscler Thromb Vasc Biol 2004; 24: 1171–1179
   PubMed Web of Science ®Google Scholar
• Bagger Y Z, Tanko L B, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728–735
   PubMed Web of Science ®Google Scholar
• Bagger Y Z, Tanko L B, Alexandersen P, Qin G, Christiansen C. Early postmenopausal hormone replacement therapy may prevent cognitive impairment later in life. Menopause 2005; 12: 12–17
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen M S, McNair P, Hagen C, Stocklund K E, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273–279
   PubMed Web of Science ®Google Scholar
• Riis B J, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987; 156: 61–65
   PubMed Web of Science ®Google Scholar
• Jensen J, Riis B J, Strom V, Christiansen C. Long-term and withdrawal effects of two different oestrogen–progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. Maturitas 1989; 11: 117–128
   PubMed Web of Science ®Google Scholar
• Haarbo J, Hassager C, Jensen S B, Riis B J, Christiansen C. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. Am J Med 1991; 90: 584–589
   PubMed Web of Science ®Google Scholar
• Bjarnason N H, Byrjalsen I, Hassager C, Haarbo J, Christiansen C. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol 2000; 183: 550–560
   PubMed Web of Science ®Google Scholar
• Christiansen C, Riis B J. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836–841
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. BJOG 2000; 107: 356–364
   PubMed Web of Science ®Google Scholar
• Alexandersen P, Riis B J, Christiansen C. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. J Clin Endocrinol Metab 1999; 84: 3013–3020
   PubMed Web of Science ®Google Scholar
• Kauppila L I, Polak J F, Cupples L A, Hannan M T, Kiel D P, Wilson P W. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245–250
   PubMed Web of Science ®Google Scholar
• Howard B V, Hsia J, Ouyang P, et al. Postmenopausal hormone therapy is associated with progression in women with abnormal glucose tolerance. Circulation 2004; 110: 201–206
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Laughlin G A. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 2005; 12: 40–48
   PubMed Web of Science ®Google Scholar
• Koh K K. Effects of estrogen on the vascular wall: vasomotor function and inflammation. Cardiovasc Res 2002; 55: 714–726
   PubMed Web of Science ®Google Scholar
• Herrington D M, Howard T D. From presumed benefit to potential harm – hormone therapy and heart disease. N Engl J Med 2003; 349: 519–521
   PubMed Web of Science ®Google Scholar
• Pradhan A D, Manson J E, Rossouw J E, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980–987
   PubMed Web of Science ®Google Scholar
• Hodis H N, Mack W J, Lobo R A, et al. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135: 939–953
   PubMed Web of Science ®Google Scholar
• Mack W J, Hameed A B, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the Estrogen in the Prevention of Atherosclerosis Trial. Atherosclerosis 2003; 168: 91–98
   PubMed Web of Science ®Google Scholar
• Davidson M H, Maki K C, Marx P, et al. Effects of continuous estrogen and estrogen–progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000; 160: 3315–3325
   PubMed Web of Science ®Google Scholar
• Koh K K, Mincemoyer R, Bui M N, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–690
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27: 261–274
   PubMed Web of Science ®Google Scholar
• Teichmann A T, Wander H E, Cremer P, et al. Medroxyprogesterone acetate and lipid metabolic changes. Arzneimittelforschung 1987; 37: 573–577
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Sagara Y. Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen. Maturitas 1996; 25: 35–44
   PubMed Web of Science ®Google Scholar
• Suparto I H, Williams J K, Cline J M, Anthony M S, Fox J L. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003; 188: 1132–1140
   PubMed Web of Science ®Google Scholar
• Tankó L B, Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 2005; 258: 544–553
   PubMed Web of Science ®Google Scholar